



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **TAKEUCHI, Kiyofumi et al.**

Group Art Unit: **1756**

Serial No.: **09/787,614**

Examiner: **Shean Chiu Wu**

Filed: **March 20, 2001**

**P.T.O. Confirmation No.: 5956**

For: **NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL  
DISPLAY DEVICE USING THE SAME**

**RESPONSE TO THE RESTRICTION REQUIREMENT**  
**DATED October 6, 2004**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

January 6, 2005

Sir:

This paper is submitted in response to the Official Action dated **October 6, 2004**, the deadline for response being extended to January 6, 2004, by a petition for a two-month extension of time.

In the Action, election is required of "a composition including each component selected from the general formula (I-1) to (I-5)." Applicant telephoned Examiner Wu for clarification of the election requirement, on October 20, 2004. Examiner Wu clarified that it is necessary to elect a second compound of one of general formulas (I-2) to (I-5), to be examined in combination with the compound of formula (I-1) previously elected.

In response, Applicant hereby elects the compound of Formula (I-2), wherein:

R<sup>1</sup> represents a propyl group,

A<sup>1</sup> represents a trans-1,4-cyclohexylene,

Response to Restriction Requirement  
U.S. Patent Application S.N. 09/787,614  
January 6, 2005

$K^1$  represents a single bond,

$A^2$  represents 1,4-phenylene,

$K^2$  represents -COO-

$k^3$  is 1,

$W^1$  represents F,

each of  $W^2$  to  $W^6$  represents H,

$k^4$  is zero,

$K^4$  is a single bond,

$X^1$ ,  $X^2$  and  $X^3$  are H, and

$Q^1$  represents F.

This general compound is shown as (I-23dg) on page 66 of the specification, with  $R^1$ ,  $X^1$ ,  $X^2$ ,  $X^3$  and  $Q^1$  being variables in that formula.

Applicant submits claims 1-4 and 13-18 read on this election.

This election is made **with traverse** of the election requirement. Applicant also notes that upon allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in independent form or include all of the limitations of the allowed generic claim as provided by 37 CFR 1.141.